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1. Introduction 
Biomarker discovery has become a major research area in proteomics as protein markers are 
more readily developed into clinical diagnostic tests than nucleic acid biomarkers. This is 
reflected by the fact that all United States Food and Drug Administration (US FDA)-
approved biomarkers currently available for clinical use are protein molecules (Srivastava, 
Verma, and Gopal-Srivastava 2005). Proteomic technologies for the global study of proteins 
have evolved in the past decade, in response to the growing demand for body fluid 
biomarker development (Anderson and Hunter 2006; Wang, Whiteaker, and Paulovich 
2009). While mass spectrometry technology is improving in sensitivity and speed, several 
technical challenges in protein biomarker discovery still requires optimization. These 
include maximizing sample throughput to process adequate number of samples, reaching 
high sensitivity, specificity and reproducibility required for FDA approval, and managing 
the costs for biomarker discovery and assay development. This chapter will discuss the 
application of a targeted proteomics approach using lectins as affinity reagent throughout 
the biomarker discovery pipeline, and automation with magnetic beads to increase 
throughput.  
2. Biomarkers 
Biomarkers are biological molecules that correlate with a disease condition or phenotype. 
The search for cancer biomarkers has increased as the traditional tumor node metastases 
(TNM) system, a morphological pathology-based system used to determine the treatment 
strategy and prognosis in cancer patients, cannot correlate cancer subtypes with clinical 
outcomes (Ludwig and Weinstein 2005). Many studies using gene expression profiling have 
been published in the past decade contributing to a detailed molecular classification of each 
tumor subtype (Srivastava and Gopal-Srivastava 2002). Genomic profiling of tumor samples 
allowed the access to individualized genomic data to determine the appropriate treatment 
method or prognosis. For example, nonsmall cell lung cancer patients with mutated 
epidermal growth factor receptor (EGFR) will be able to receive an inhibitor of the EGFR 
tyrosine kinase activity called gefitinib (Belda-Iniesta, de Castro, and Perona 2011). The 
availability of specific non-invasive biomarkers will facilitate this type of tailored or 
personalized medicine to improve therapy and patient outcomes.  
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2.1 Types of biomarkers 
Biomarkers can be divided into types based on clinical significance; including predictive, 
detection, diagnostic and prognostic markers (Mishra and Verma 2010). Predictive markers 
or response markers are used to assess the response of a specific drug to allow selection of 
appropriate treatment regimes for each patient. For example, in breast cancer patients, 
Her2/Neu overexpression will lead to treatment using Herceptin®, whereas for other types 
of breast cancer, tamoxifen provides the best patient outcomes (Hudis 2007). Thus, Her-
2/Neu is a predictive cancer biomarker for some breast cancer therapies (Roses et al. 2009). 
Likewise, drugs such as INGN 201 (ADVEXIN®), which targets abnormal p53 tumor 
suppressor function, can be administered as monotherapy or in combination with radiation 
and/or chemotherapeutic agents in cancers showing abnormal p53 function (Gabrilovich 
2006). Pharmacodynamic markers are used to select the appropriate dose of 
chemotherapeutic drugs. These markers help in optimizing cancer drug doses to minimize 
cytotoxicity and are often used in clinical trials. Mitogen-activated protein kinase (MAPK), 
Akt, or p27 which are downstream receptor-dependent molecules of phosphorylated EGFR 
are pharmacodynamic biomarkers for certain EGFR tyrosine kinase inhibitors (Albanell, 
Rojo, and Baselga 2001). Diagnostic markers can be used for early detection, determination 
of stage, tissue or relapse (Verma and Manne 2006). For example, the presence of bladder 
tumor antigen (BTA) and nuclear matrix protein-22 (NMP-22) in urine indicates the 
presence of bladder cancer (Lau et al. 2009) and serum alpha-fetoprotein is useful to 
diagnose nonseminomatous testicular cancer (Sturgeon et al. 2008). Prognostic biomarkers 
are used to discriminate benign from malignant tumors. For example, human 
papillomavirus (HPV) associated in oral cancer has a better survival time compared to other 
types of oral cancer (Mishra et al. 2006). Commercially available tests based on the genetic 
expression of the virus can be used to determine the prognosis. Some biomarkers can have 
overlapping uses, i.e. carcinoembryonic antigen (CEA) is used as a prognostic and 
diagnostic marker and so can be used in postoperative surveillance and monitoring of the 
effectiveness of therapy in advanced colorectal cancer (Sturgeon et al. 2008).  
Biomarkers can be based on any biomolecule including DNA, RNA, protein, and 
carbohydrate markers (Mishra and Verma 2010). Single nucleotide polymorphisms (SNP), 
loss of heterozygosity, copy number variants, chromosomal aberrations such as 
microsatellite instability and epigenetic modifications, and mutations in oncogenes or tumor 
suppressor genes are all examples of DNA markers (Ludwig and Weinstein 2005). RNA 
markers are usually identified from microarray analysis, and can be validated using qRT-
PCR (Gray and Collins 2000). The potential of microRNAs (miRNA) or small non-coding 
RNAs for use as cancer biomarkers has also been documented (Bartels and Tsongalis 2009). 
DNA and RNA markers have improved the molecular characterization of specific tumors 
and their subtypes, but the practical usefulness in the clinical setting may be limited as the 
tests involve intensive processing, and are far from being noninvasive, simple and cost 
effective. Protein biomarkers are clinically useful because cancer cells secrete or shed 
proteins and peptides into body fluids, allowing minimally invasive tests. Hence mass 
spectrometry based proteomics techniques have evolved with a purpose driven aim to 
discover novel protein biomarkers. 
2.2 Biomarker discovery 
Ideal biomarker tests should be noninvasive, cheap, simple to perform, informative and 
accurate (Boja et al. 2011; Negm, Verma, and Srivastava 2002; Srivastava and Gopal-
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Srivastava 2002). The process of developing such a test is a difficult and uncertain task, as 
reflected by the declining number of newly approved biomarker tests by the FDA. However, 
despite this, there are a growing number of articles published on potential biomarker 
candidates (Anderson and Anderson 2002; Polanski and Anderson 2007; Rifai, Gillette, and 
Carr 2006). Depending on the purpose of the biomarker and its application in clinics, the 
criteria and developmental approach for each biomarker varies. The conventional biomarker 
discovery pipeline involves five stages. Clearly defined issues should be addressed at each 
stage to guide the process through to success (Fig. 1) (Surinova et al. 2011; Pepe et al. 2001).  
 
 
Fig. 1. Biomarker discovery workflow and study objectives for each phase. Modified from 
Pepe et al. (Pepe et al. 2001) 
Phase 1 - Preclinical Discovery phase. Phase 1 is dedicated to hypothesis driven 
identification of candidate biomarkers, ranking and/or finding suitable combinations of 
potential biomarkers. The clinical question is defined and a small number of samples are 
obtained and analyzed to generate a list of candidates with their fold changes (Pepe et al. 
2001).  
Phase 2 – Preclinical verification. Phase 2 evaluates the (ranked) list of potential biomarkers 
generated in phase 1 using clinical samples from cases with known diagnosis. The end point 
of the assay may be mean concentration of candidate protein(s) or a unique signature 
associated with either one of the groups (Alonzo, Pepe, and Moskowitz 2002). The 
reproducibility, dynamic range and limit of detection (sensitivity) are determined in a 
relatively small cohort of patients, but with more patients than phase 1 (Rifai, Gillette, and 
Carr 2006). Another aim of the verification phase is to determine the sample size required 
for the Preclinical validation phase, to achieve statistical significance.  
Phase 3 – Preclinical validation. The third phase is still within the scope of preclinical 
assessment but the aim is to generate a disease signature to determine whether the study 
objective can be met by the platform. The control and patient groups are designed 
retrospectively and the numbers used depend on the sensitivity and specificity of the 
biomarker determined in the previous phase, and the prevalence of the cancer in the 
population. The results are evaluated for analytical performance including test accuracy and 
precision, and clinical performance (Gutman and Kessler 2006), which must meet single-
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digit measurement coefficient-of-variation values (CVs) from measurement of thousands of 
patient samples. If the performance of the optimized assay meets the clinical objective, the 
process proceeds to the next phase, clinical evaluation. 
Phase 4 – Clinical evaluation. Phase 4 is the development of a clinical assay and clinical 
evaluation of the biomarker as an in vitro diagnostic test. This phase is prospective and 
involves new control subjects and patients who are yet to be diagnosed (Manolio, Bailey-
Wilson, and Collins 2006). The patient group sizes increase again based on the results from 
phase 3. The aim of phase 4 is to fulfil the clinical requirements and determine the true 
positive and false positive rates.  
Phase 5 – Disease control. The last phase aims to determine the effect of the biomarker on 
disease management in the target population. Therefore, the biomarker proceeds into phase 
5 when it is approved and accepted for clinical use. Phase 5 consists of the largest sample 
size and thus takes many years to complete. Data pertaining to cost of the test, as well as the 
consequences from the use of the biomarker are determined. 
Biomarker development has had limited progress due to the lack of effective technology, 
established guidelines for designing clinical sample groups in each phase, standardized 
procedures for the development of the biomarker pipeline and quality assessment of the 
studies published (Mischak et al. 2007; Surinova et al. 2011). Therefore, by addressing the 
study objective clearly and by applying considerations for each phase, biomarker research 
should lead to more translatable candidates in the clinical context.  
3. Proteomics for biomarker discovery  
As described above, the road to discover biomarkers is a long and uncertain path consisting 
of different stages and multiple validation steps. The decisions made especially in the first 
few phases on the ranking of  candidates or the best combination of candidates to maximize 
the sensitivity and specificity have enormous effects on the outcome of a successful 
biomarker assay. Consistency in the proteomics techniques and sample type used for each 
phase is crucial to successful biomarker discovery and validation. 
3.1 Choice of sample type  
The choice of sample type may be determined by availability, as well as complexity of the 
sample type for the available technology. Although the final preferred outcome are body 
fluid (commonly blood) tests, plasma or serum as a sample for proteomics is technically 
challenging due to dilution of potential biomarkers and the presence of high abundance 
proteins masking the lower abundance disease-associated proteins. Estimates suggest that 
there are more than 106 proteins in the blood proteome while one protein (albumin) 
accounts for more than half of all blood proteins (Zhang, Faca, and Hanash 2011). 
Approximately 22 proteins, including globulins, transferrins and fibrinogen make up 99% of 
the total blood proteins. Additionally, the concentration of a blood protein can range from 
less than 1-5 pg/ml to more than 55 billion pg/ml, stretching across seven logs (Zhang, 
Faca, and Hanash 2011).  
Immunodepletion columns have been developed to remove the top 6, 7, 12, 14, or 20 
proteins from plasma/serum, prior to proteome profiling (Smith et al. 2011; Gong et al. 
2006; Tu et al. 2010). However, this procedure may also deplete potential proteins of interest 
that are bound to albumin in the blood stream, as well as low abundance proteins due to 
non-specific binding (Gong et al. 2006). Due to these technical difficulties, many studies 
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choose to use tissue samples in the discovery phase; however, it is difficult to predict which 
proteins will be easily detected in the blood as data derived from tissue is not always 
translatable to blood (Abbott and Pierce 2010). Therefore, direct analysis of plasma or serum 
rather than tissue may be useful in the initial discovery phase (Rifai, Gillette, and Carr 2006; 
Kulasingam and Diamandis 2008).  
3.2 Choice of technology 
Ideally, similar or compatible techniques are used throughout the biomarker discovery and 
validation pipeline. However, no single technique can fulfill the requirements of all 5 phases 
with sufficient throughput, sensitivity and accuracy. Phase 1 requires the measurement of 
thousands of analytes in few samples, while phases 2-4 require the (simultaneous) 
measurements of fewer analytes in increasing number of samples. Furthermore, clinical 
assays (phase 4-5) ideally requires minimal sample handling. 
Current proteomic profiling methods used in the discovery phase are not suitable for later 
phases since techniques such as two-dimensional difference gel electrophoresis (2D-DIGE) 
and multidimensional protein identification technology (MuDPIT) can only analyze one 
sample at a time, and require days of processing. Current technologies for preclinical and 
clinical phases such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay 
(ELISA) and multiplex fluorescent detection technology are antibody-based assays requiring 
identified target, and hence not applicable to the discovery phase. The development and use 
of Selected Reaction Monitoring mass spectrometry (SRM-MS) as pre-clinical and 
potentially clinical assays not only provide a link between discovery, validation and clinical 
techniques, it also avoids the significant cost outlay for antibody development. Hence SRM-
MS technology is fast becoming the method of choice for pre-clinical phases, and is set to 
make it into the clinical arena.  
3.3 Improving throughput  
Due to the high cost and low sample throughput in proteomics technology, biomarker 
discovery workflows have commonly suffered from the lack of sufficient technical and 
biological replicates. To address these short-comings, significant effort has been spent on 
sample preparation and separation using automation on robotic liquid handler, and the 
introduction of nanomaterial for nanoproteomics (Ray et al. 2011). Increased throughput in 
mass spectrometry can be achieved by means of multiplexing samples (Boersema et al. 2009; 
Chen et al. 2007) and/or shortening bioinformatic analysis time after the generation of mass 
spectrometry data (Martens 2011a, 2011b). 
3.4 Targeted proteomics  
Discovery proteomics workflows generally require multiple steps of separation due to high 
sample complexity. One strategy to reduce extensive separation steps is to enrich for a 
subset of proteins that are disease-relevant. In this chapter, we focus on the potential of 
targeted glycoproteomics as an all-encompassing technology for the phases of (glyco-) 
biomarker discovery. 
4. Glycoproteomics 
Glycoproteomics, an area of proteomics with biological and clinical significance, is an 
emerging field in biomarker research (Pan et al. 2011; Meany and Chan 2011). 
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Glycoproteins are a group of proteins in which one or more glycans (sugars) are covalently 
bonded to the protein through a process called glycosylation. There are two main types of 
protein glycosylation: (i) N-linked glycosylation whereby the glycan is attached to the 
amide nitrogen of asparagine in a consensus Asparagine-X-Serine/Threonine (Asp-X-
Ser/Thr) sequence, where X can be any amino acid except proline and (ii) O-linked 
glycosylation in which the glycan is attached to the hydroxyl oxygen of serine or threonine 
in the protein. Glycosylation is the most abundant posttranslational modification and the 
most structurally diverse. There are at least 14 different monosaccharides and 8 different 
amino acids involved in this process with at least 41 different chemical bonds in glycan-
protein linkage. 
Glycoproteins are important targets in the search for biomarkers for the following 
reasons: (i) more than 50% of secreted proteins are glycoproteins, (ii) glycosylation 
changes in tissues, blood and serum from patients with disease has been implicated in 
pathogenesis, (iii) changes in glycosylation can be more distinctive than changes in 
protein expression, as specific glycan structures are generally not present normally, but 
increase in disease states, (iv) changes in glycosylation occur in many proteins including 
abundant proteins, thus increasing the likelihood of early detection, (v) the glycosylated 
form of a particular protein site is generally stable for a given cell type and physiological 
state, and (vi) as one of the important functions of glycans is in cell-cell interactions and 
consequently the control of cell function, alterations of protein glycosylation can be 
diagnostic for a disease (Pan et al. 2011; Packer et al. 2008). Altered glycosylation can be 
seen in diseases as hypo, hyper or newly glycosylated sites, and/or altered carbohydrate 
moieties (Pan et al. 2011).  
Although advances in technologies used in glycoprotein research has been slow due to the 
complicated nature and vast variety of changes in glycosylation, advances in proteomic 
technologies have facilitated glycoproteomics research. An excellent example of a glyco-
biomarker is alpha-fetoprotein (AFP), a marker for hepatocellular carcinoma (HCC) 
(Sturgeon et al. 2010). The specificity for AFP in HCC is low, limiting the use in the clinic 
(Meany, Sokoll, and Chan 2009), however, recent studies have shown that the fucosylated 
form of AFP which is highly reactive with the Lens culinaris agglutinin, also known as AFP-
L3, improves the specificity (Masuda and Miyoshi 2011), demonstrating the utility of glyco-
biomarkers.  
4.1 Glycoproteomic approaches for biomarker discovery 
A typical glycoproteomics pipeline consists of glycoprotein enrichment techniques, followed 
by multidimensional chromatographic separation, and mass spectrometry with 
bioinformatic data analysis. Glycoproteomics approaches can be divided into glycoprotein-
based and glycopeptide-based methods (Fig. 2). Glycoprotein-based enrichment methods, 
also known as the top-down workflow, enrich for the glycoproteins prior to proteolytic 
digestion with enzymes such as trypsin. Glycan cleavage is performed before or after 
proteolytic digestion. In glycopeptide enrichment methods, proteolytic digestion is 
performed before enrichment. This is also known as the bottom-up workflow. The bottom-
up workflow is more popular as it provides detailed information of a glycoprotein profile, 
and also specific mapping of glycosylation sites. However, the bottom-up workflow can 
result in very low sample throughput, and current technology is not capable of determining 
detailed glycan structure of glycoproteins in one analysis (Pan et al. 2011). On the other 
hand, the top-down workflow may not accurately provide mapping of glycosylation sites,  
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Fig. 2. Glycoproteomic approaches for glycan, deglycosylated and intact glycopeptide 
analysis. In the top-down workflow, glycoprotein enrichment is performed which may or 
may not follow deglycosylation. In the bottom-up workflow, proteins are digested then 
glycopeptides are enriched for further analysis. 
although it results in greater glycoprotein sequence coverage. Therefore, the technique used 
will depend on the specific research question asked.  
4.2 Glycoproteome enrichment techniques 
Several techniques have been used for enrichment of glycans, glycopeptides and 
glycoproteins (Tousi, Hancock, and Hincapie 2011; Rakus and Mahal 2011; Pan et al. 2011), 
including hydrazide chemistry-based solid phase extraction methods, boronic acid-based 
solid phase extraction, size exclusion chromatography, hydrophilic interaction liquid 
chromatography (HILIC), activated graphitized carbon and lectin affinity based methods 
(Table 1). This chapter will discuss the potential of lectins as a universal enrichment tool in 
all phases of the glyco-biomarker discovery workflow. Lectins are naturally occurring sugar 
binding proteins which are highly specific for their sugar moieties. Their abilities to 
recognize and bind to specific glycans make them ideal for glycan structure specific 
glycoprotein enrichment. Lectins have been used in biological research as an affinity reagent 
for the past few decades, with applications such as lectin histochemistry (Brooks et al. 1996; 
Carter and Brooks 2006), lectin blotting (Welinder et al. 2009), lectin-affinity 
chromatography in combination with mass spectrometry (Abbott and Pierce 2010; Yang et 
al. 2006; Zhao et al. 2006; Xu et al. 2007; Qiu et al. 2008; Jung, Cho, and Regnier 2009) and 
lectin microarray (Gupta, Surolia, and Sampathkumar 2010; Katrlik et al. 2010) to examine 
the glycoproteome of serum and plasma.  
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Table 1. Glycoproteome enrichment techniques 
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5. Use of lectins in glyco-biomarker discovery 
The potential of a lectin-enrichment step to be coupled to different downstream assay 
techniques is attractive in glyco-biomarker discovery as it reduces the potential variation 
introduced by the change of enrichment methods going from one phase to another (Fig. 3). 
For example, in the discovery workflow of phase 1, lectin-enrichment can be followed by 
glycoprotein or glycopeptide separation and identification by tandem mass spectrometry 
(MS/MS), to measure hundreds of analytes. In the preclinical stages (phases 2 and 3), lectin 
affinity isolation may be coupled to SRM-MS for targeted quantification of a reduced 
number of candidates. Although SRM-MS assays may have the desired sensitivity and 
reproducibility, routine use in clinical pathology laboratories will need additional 
technology optimization. Lectin affinity can also be incorporated into other preclinical 
verification technology such as multiplexed immunoassay incorporating fluorescence-
labeled microspheres with specific antibodies (Li et al. 2011), multiplexed protein analysis 
using antibody-conjugated microbead arrays (Theilacker et al. 2011), and multiplex proteins 
assays using magnetic nanotag sensing (Osterfeld et al. 2008). For clinical phases 3-5, 
existing antibodies may be used or antibodies may be developed for use in lectin 
microarrays or lectin-immunosorbent assays. 
 
 
Fig. 3. Biomarker discovery pipeline using lectins. 
5.1 Lectin affinity chromatography for glyco-biomarker discovery  
Lectin affinity chromatography is a technique that employs one or more lectins to enrich for 
structurally similar subset(s) of glycoproteins or glycopeptides (Jung, Cho, and Regnier 
2009; Durham and Regnier 2006; Yang et al. 2006). By coupling this technique to mass 
spectrometry analysis, bound and unbound fractions can be analysed to identify proteins in 
the two fractions. Lectin affinity chromatography can be performed in different formats 
including tubes, packed columns, microfluidic channels and high pressure liquid 
chromatography (HPLC) (Mechref, Madera, and Novotny 2008). Different types of support 
matrices can be used to immobilize the lectins, such as sepharose/agarose beads (Kobata 
and Endo 1992; Mechref, Madera, and Novotny 2008), magnetic beads (Lin et al. 2008), silica 
or styrene-divinylbenzene co-polymers coated with a cross-linked polyhydroxylated 
polymer (POROS) (Tousi, Hancock, and Hincapie 2011). Commonly used lectins include 
mannose and glucose binding concanavalin A (ConA) and N-acetylglucosamine binding 
wheat germ agglutinin (WGA) for their broad binding specificities and affinity to most N-
linked glycans in biological material. For O-linked glycans, jacalin (JAC) is added to these 
two lectins for a global range of glycoprotein enrichment. For more specific enrichment, 
sialic acid and/or fucose binding lectins can be used, such as Sambucus nigra agglutinin 
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(SNA) and Maackia amurensis agglutinin (MAA) for sialic acid and Aleuria aurantia lectin 
(AAL) for fucose. A wide range of different sample types have been used including soluble 
and membrane derived glycoconjugates from serum/plasma, cell lysates and tissue 
homogenates. Elution of bound glycoproteins/peptides is commonly achieved using 
competitive sugar of relatively low concentrations (5-100 mM) (West and Goldring 1996) or 
low pH such as acidic solutions (Green, Brodbeck, and Baenziger 1987).  
Lectin affinity chromatography can be incorporated into top down or bottom up proteomics 
workflows, where the glycoproteins or the glycopeptides are identified by LC-MS/MS, 
respectively. Top down workflows identify lectin-reactive glycoproteins primarily by the 
non-glycosylated peptides in the isolated glycoproteins. The advantages are high sensitivity 
and ease of use, but the top down approach does not identify the actual glycopeptide(s) that 
bound to the lectins. Bottom up workflows directly identify the captured glycopeptides, but 
is technically more challenging due to the lower amount of targets. Top down and bottom 
up approaches generate complementary data and have both been successfully applied in 
glyco-biomarker discovery (see 5.1.2). 
Modified versions of lectin affinity chromatography has been reported including Serial 
Lectin Affinity Chromatography (S-LAC) which uses a series of sequential lectin affinity 
steps (Durham and Regnier 2006) or Multi-lectin Affinity Chromatography (M-LAC) which 
combines 3 or more different lectins for one-step isolation (Yang and Hancock 2004; Ahn et 
al. 2010; Na et al. 2009). Both methods can be incorporated into the top down and bottom up 
workflow. However, the bottom up workflow is preferred for S-LAC as proteins with more 
than 1 glycosylation site with binding affinity to both lectin, may not be identified by the 
second lectin. S-LAC using ConA and JAC was shown to be efficient for enriching O-linked 
glycopeptides, since ConA removes most N-linked glycopeptides containing mannose 
which will facilitate the binding of O-linked glycopeptides to Jacalin (Durham and Regnier 
2006). M-LAC is also an effective system to simplify complex samples allowing enrichment 
of approximately 50% of the plasma proteome in one-step (Dayarathna, Hancock, and 
Hincapie 2008). The bound fraction of M-LAC using ConA, WGA and JAC has been used by 
Zeng and others for the initial identification of candidate biomarkers in serum from breast 
cancer patients (Zeng et al. 2011). M-LAC was coupled with 1D SDS-PAGE, isoelectric 
focusing and lectin-overlay antibody microarray to identify several glycoproteins such as 
alpha-1B-glycoprotein and complement C3 as potential candidates (Zeng et al. 2011). 
Kullolli et al. further developed M-LAC into a high performance multi-lectin affinity 
chromatography (HP-MLAC), involving targeted albumin and immunoglobulin depletion 
in-line with glycoprotein affinity isolation using M-LAC (Kullolli, Hancock, and Hincapie 
2010). This method has shown reproducibility and consistency of the bound and unbound 
fraction over 200 runs which promises to provide quality plasma glycoproteome data for 
clinical proteomics. 
5.1.1 Technical aspects of lectin affinity enrichment 
Although widely used, significant binding of non-glycosylated proteins during lectin 
affinity enrichment has been reported (Lee et al. 2009). Potential causes of the non-specific 
binding include the presence of protein complexes and prolonged incubation leading to 
non-specific binding to support beads. To optimize binding conditions, we investigated 
glycoprotein capture using Concanavalin A (ConA)-magnetic beads with a range of mild to 
stringent binding buffers, using a short incubation time of 30 minutes (Loo, Jones, and Hill 
2010). In order to disrupt protein-protein complexes which may result in binding of non-
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glycosylated proteins to lectin beads, we included a reducing agent (1 mM DTT) and a 
strong detergent (0.2% SDS) in the binding and washing steps. Although this resulted in 
~20% loss of protein binding compared to previous lectin-affinity buffer (Yang et al. 2006), 
we still observed strong affinity between lectin and their cognate glycans (Loo, Jones, and 
Hill 2010). Using the most stringent buffer condition, we have shown reproducibility of 
lectin-glycoprotein binding, confirming this buffer condition helps to avoid non-specific 
binding of lectins while enriching for glycoproteins with the highest affinity to the 
individual lectins (Loo, Jones, and Hill 2010).  
5.1.2 Application of lectin affinity enrichment in biomarker discovery 
Top down workflows that incorporate lectin affinity chromatography have been used to 
identify potential biomarkers in diseases including psoriasis (Plavina et al. 2007), 
hepatocellular carcinoma (Na et al. 2009), diabetic nephropathy (Ahn et al. 2010) and 
bladder cancer (Yang et al. 2011). Plavina et al. depleted the two most abundant plasma 
proteins, albumin and immunoglobulin, and performed M-LAC consisting of ConA, WGA 
and JAC to identify numerous tissue leakage proteins present in plasma at low ng/mL 
concentrations, such as galectin-binding protein 3, which was subsequently verified by 
ELISA (Plavina et al. 2007). Na et al. used M-LAC consisting of ConA, WGA, JAC, SNA, and 
AAL and 2D-DIGE with liver tissue samples to identify human plasma carboxylesterase 1 as 
a potential biomarker for hepatocellular carcinoma (Na et al. 2009). Ahn et al. used M-LAC 
to capture plasma glycoproteins and found 13 up-regulated and 14 down-regulated 
glycoproteins in diabetic nephropathy (Ahn et al. 2010). Yang et al. used ConA and WGA 
for dual-lectin affinity chromatography to enrich for glycoproteins in urine to identify 
biomarker candidates for bladder cancer and identified 265 glycoproteins with higher 
abundance in the cancer group compared to the control group (Yang et al. 2011). While there 
was an overlap of the proteins identified, 240 glycoproteins were uniquely identified by 
each of the methods. Furthermore, lectin affinity chromatography of glycoproteins has been 
used for a cell cycle study which combined MAA-affinity chromatography of glycoproteins 
from cell lysates of the cervical cancer cell line, HeLa cells, and periodate labeling of 
membrane proteins of intact cells coupled to hydrazide chemistry, to identify distinct 
expression patterns during the cell cycle which demonstrated a 4-fold change in membrane 
protein expression during different cell cycles (McDonald et al. 2009).  
Bottom up lectin-affinity has also been successfully applied in glyco-biomarker discovery. 
For example, Drake et al. utilized immunoaffinity depletion and subsequent M-LAC with 
SNA and AAL to identify 122 human plasma glycoproteins with 247 unique glycosites 
(Drake et al. 2011). Alvarez-Manilla et al. used ConA-sepharose to identify 18 glycoproteins 
unique to mouse embryonic stem cells and 45 proteins exclusively found in cells of 
differentiated embryoid bodies (Alvarez-Manilla et al. 2010). Furthermore, the bottom up 
method coupled with filter-aided sample preparation (FASP) was shown to detect 6367 N-
glycosites on 2352 proteins which accounts for 74% of known mouse N-glycosites and 5753 
unique sites in four mouse tissues and blood plasma, demonstrating the ability of lectin 
affinity chromatography techniques to enrich for glycopeptides (Zielinska et al. 2010).  
5.2 Lectin magnetic bead array for high-throughput glyco-biomarker discovery and 
preclinical verification 
Differential binding to a panel of lectins (a lectin signature) can be used as disease 
biomarker. This is the principle behind lectin microarrays (see section 5.3) for known target 
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proteins, however, there is a lack of high-throughput methodology for de novo discovery of 
lectin signatures for potential glyco-biomarkers. To this end, we introduced the concept of a 
high-throughput lectin-magnetic bead array (LeMBA), consisting of a panel of individual 
lectin-magnetic beads arrayed in a microplate (Loo, Jones, and Hill 2010). The use of 
magnetic beads allows liquid handler-assisted automation to increase the throughput while 
assessing individual lectin-binding sub-glycoproteomes. Direct coupling to LC-MS/MS for 
glyco-protein (top down) or glyco-peptide (bottom up) analysis enables the simultaneous 
identification of glyco-biomarker and its lectin signature.  
While most (glyco-)biomarker discovery workflows focus on low abundance proteins in 
the serum/plasma, LeMBA-MS screens for specific glycan structure changes by 
determining the lectin signatures of the glyco-proteome. Hence, instead of identifying 
new, low abundance proteins secreted or leaked by the diseased cells, the LeMBA 
approach focuses on alteration in the glycosylation structure of medium- to high-
abundance secreted proteins. Since altered glycosylation of secreted and/or cell surface 
proteins reflects cell function and hence disease progression (Pan et al. 2011; Packer et al. 
2008), this approach is likely to discover disease-relevant glyco-biomarkers. Previous 
studies aimed to find glyco-biomarkers have identified high abundance proteins in the 
blood as potential biomarker candidates, such as haptoglobin (Yoon et al. 2010; Fujimura 
et al. 2008), hemopexin (Comunale et al. 2009), transferrin (Zeng et al. 2011; Bones et al. 
2010) and alpha-1B-glycoprotein (Zeng et al. 2011).  
LeMBA results will be trading low abundance for high specificity as glycosylation changes 
detected by multiple lectins will be unique for the altered glycan structure. This approach 
also holds promise for early diagnostic biomarkers since detection of low abundance early 
diagnostic markers is extremely difficult to achieve with any throughput using the current 
detection systems and workflows. If glycosylation changes are identified in early stages of 
diseases in medium to high abundance proteins, these changes can be developed into 
biomarkers with reasonable sensitivity and specificity as the proteins carrying the altered 
glycan will be easy to detect. 
Taken together, it is expected that candidate biomarkers resulting from LeMBA-MS screen 
will increase the sensitivity and specificity of glyco-biomarker, owing to the ability of lectin 
signatures to identify overall and subtle changes. For biomarker discovery phase 2, 
combinations of lectin signatures that show the biggest changes between normal and disease 
will result in a panel of potential biomarker candidates that can be verified using LeMBA 
coupled to SRM-MS for verification and antibody-overlay lectin microarrays for further 
validation (Boja and Rodriguez 2011). 
5.3 Lectin microarray as high-throughput glyco-biomarker validation assay 
Since their introduction in 2005, lectin microarrays have emerged as a new technology that 
utilizes lectins as a glyco-profiling tool. A typical microarray contains 6 to 43 lectins 
immobilized on a solid surface and binding of glycoproteins to lectins is, in most cases, 
detected by standard fluorescence microarray scanners (Gemeiner et al. 2009). Lectin 
microarrays are a rapid, sensitive and high-throughput screening tool, highly suitable for all 
phases of glyco-biomarker discovery, depending on the type used. 
5.3.1 Types of lectin microarrays and their use in biomarker discovery 
Generally, there are two types of lectin microarrays: the direct assay and reverse-phase dot-
blot lectin array (Gemeiner et al. 2009; Gupta, Surolia, and Sampathkumar 2010). The direct 
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assay format immobilizes lectins on a solid surface and applies prelabeled sample over the 
surface. On the other hand, reverse-phase dot-blot lectin array immobilizes glycoproteins on 
a solid surface and applies prelabeled lectins. These two types have been used for biomarker 
discovery phase 1 for pancreatic cancer (Li et al. 2009; Patwa et al. 2006; Liu et al. 2010), 
glioblastoma (He et al. 2010), HCC (Zhao et al. 2007) and colorectal cancer (Qiu et al. 2008) 
to investigate differential glycosylation between control and disease. 
The direct assay can also be modified into a sandwich assay called the antibody-overlay 
lectin microarray (ALM) or lectin-overlay antibody microarray (LAM). In ALM, lectins are 
immobilized on a solid surface; glycoproteins are added, followed by a biotinylated 
antibody overlay that binds to the protein. Then, streptavidin with a fluorophore attached is 
added, and the fluorescence is detected. The difference between ALM and LAM is that in 
LAM, the antibody is attached to a solid surface and biotinylated lectins are overlaid to bind 
to the glycan structure (Fig. 4). These types of lectin microarrays may be used for biomarker 
discovery phase 3 and higher and can be developed into clinical assays with a condition that 
they are reproducible with less than 10% CV (Fung 2010).  
 
 
Fig. 4. Different types of lectin microarrays. 
5.3.2 Technological aspects of lectin microarrays for phase 3 and above biomarker 
assay development 
Preserving the carbohydrate recognition domain (CRD) is important for the reproducibility 
of the assay for assays with immobilized lectins. Popular methods of lectin immobilization 
include adsorption on nitrocellulose, attachment of amine functional group of protein 
backbone of lectins to a solid surface through epoxy- or N-hydroxysuccinimidyl-derived 
ester coated glass slides (Kuno et al. 2005) and use of self-assembled monolayers of thiols on 
gold-coated surfaces (Zheng, Peelen, and Smith 2005). Other methods include biotinylated 
lectin-neutravidin bridging (Angeloni et al. 2005), DNA-driven immobilization of lectins on 
polystyrene latex particles (Fromell et al. 2005), and binding to hydrogel based surfaces 
(Koshi et al. 2006). Unfortunately, no method can control for the optimal orientation of the 
CRD of lectins, to maximize the lectin binding ability and for the reproducibility of the 
assay. Techniques such as covalent bonding of lectins by carbenes have shown to 
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immobilize the lectins but failed to preserve the carbohydrate binding activity (Angeloni et 
al. 2005) indicating the importance of preserving the CRD of lectins when lectin arrays are 
generated. The lack of control for lectin immobilization may lead to increased variation of 
assays. The variations of spotting have been reported to be 10-20% (Kuno et al. 2005) and the 
variation of a reverse-phase dot-blot assay, 10% (Patwa et al. 2006), which may be too high 
to qualify for FDA approval. To preserve the CRD, it has been suggested that glycans of 
glycosylated lectins may be used as an anchor point for attachment, followed by anchoring 
to hydroxylamine or hydrazine containing solid surface, which would preserve the CRD of 
the lectin (Gupta, Surolia, and Sampathkumar 2010). Of course, not all lectins are 
glycosylated, but this may help lower the variation of a biomarker assay. Additionally, the 
LAM type may be more suitable for phase 3 and above biomarker assays to avoid this issue. 
As in most protein arrays, binding is, in most cases, detected by fluorescence (Pilobello and 
Mahal 2007; Gemeiner et al. 2009) using fluophores such as Cy3/Cy5, Alexa Fluor 555, and 
phycoerythrin. A number of different technologies have been introduced to increase the 
sensitivity of detection and salvage weak lectin-glycan bonds. Kuno et al. have introduced the 
use of evanescent-field fluorescence which allows in situ detection without a washing step to 
wash away any unbound material (Kuno et al. 2005). However, this technique requires a 
specialized evanescent-field fluorescence scanner. Other methods proposed include a 
modified fluorescence resonance energy transfer (FRET) method which demonstrated that a 
biomolecular fluorescence quenching and recovery (BFQR) technique can be used together 
with a supramolecular hydrogel matrix for the selective recognition of lectin-glycan bonds in 
reverse-phase dot-blot assays (Koshi et al. 2006). The use of tyramide signal amplification 
(TSA), which is a horseradish peroxidase (HRP)-mediated signal amplification method for 
ALM, has also shown to enhance signaling and therefore, increase the sensitivity of ALM over 
100 times and allowed the detection of weak lectin-glycan interactions as demonstrated with 
as low as 20 ng of prostate specific antigen from seminal fluid (Meany et al. 2011).  
6. Conclusions 
There is no doubt that advancement in proteomics has and will contribute to protein 
biomarker discovery. Especially, technological advancement has enabled glyco-biomarker 
research. Medium to high abundance blood glycoproteins with disease-specific 
glycosylation structures are attractive as glyco-biomarkers, with potential for development 
of robust clinical assays compared to low abundance blood proteins. However, there is still 
a general lack of high-throughput glycoproteomics platforms to facilitate the discovery and 
validation of candidate glyco-biomarkers. The technologies and sample types used in the 
phases of glyco-biomarker discovery are critical to the final outcome, that is, development of 
a clinical assay.  
In this chapter, we highlight the potential of lectins as a unifying glycan affinity tool for 
glyco-biomarker discovery. Lectin-based glycoprotein enrichment methods such as lectin 
affinity chromatography and high-throughput LeMBA can be coupled with LC-MS/MS to 
generate candidate biomarkers (phase 1 biomarker discovery). After the discovery of 
potential biomarkers, lectin affinity techniques such as LeMBA can be coupled to SRM-MS 
for high-throughput verification of a large number of patient samples. Finally, for phase 3 
and onwards, ALM or LAM type lectin microarrays or lectin-coupled immunosorbent 
assays can be used for further validation of the biomarker assay to ensure high clinical and 
analytical performance. Having a unifying affinity reagent will improve the consistency 
and, therefore, success rate of transfer between the phases of biomarker discovery.  
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Combined with the appropriate bioinformatics tools, such as the recently developed serum 
glycopeptide SRM atlas (Schiess, Wollscheid, and Aebersold 2009) and glycan databases 
(reviewed in Frank and Schloissnig 2010), glyco-biomarker discovery and validation will 
surely contribute to biomarker research. 
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